KMT2A and acute myeloid leukemia: Overall, our findings suggest that DS-1594a·HCl and DS-1594a·succinate may achieve CR without minimal or measurable residual disease (MRD) in individuals with MLL1-r AML even as single agents by inducing strong AML cell differentiation and exhibiting durable efficacy via potential LIC depletion, as MRD and LICs are major contributors to relapse in AML.